Revelation Biosciences, Inc. Common Stock (REVB) is a publicly traded Healthcare sector company. As of September 21, 2026, REVB trades at $0.98 with a market cap of $3.71M and a P/E ratio of -0.05. REVB moved +0.00% today. Year to date, REVB is -70.92%; over the trailing twelve months it is -85.09%. Its 52-week range spans $0.88 to $56.40. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces REVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for REVB, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $0.98 |
| Market Cap | $3.71M |
| P/E Ratio | -0.05 |
| EPS | $-19.37 |
| Dividend Yield | 0.00% |
| 52-Week High | $56.40 |
| 52-Week Low | $0.88 |
| Volume | 13.94K |
| Avg Volume | 0 |
| Revenue (TTM) | $165.99K |
| Net Income | $-10.75M |
| Gross Margin | 0.00% |
1 analysts cover REVB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.